Sana Biotechnology– tag –
-
Sana Biotechnology Targets 2026 IND for iPSC-Derived Hypoimmune Pancreatic Islet Cell Therapy SC451 in Type 1 Diabetes
TipRanks / Sana Biotechnology, Inc. USA Overview Sana Biotechnology updated its investor presentation, emphasizing pipeline advancements, particularly for SC451, an iPSC-derived hypoimmune pancreatic islet cell therapy for Type 1 diabete... -
Sana Biotechnology Advances Hypoimmune iPSC-Derived SC451 for Type 1 Diabetes and In Vivo CAR T SG293 for Non-Hodgkin Lymphoma Towards Clinical Entry, Bolstered by NEJM Publication of Long-Term Pancreatic Islet Data
Sana Biotechnology, Inc. (Press Release) USA Overview Sana Biotechnology reported significant progress towards initiating clinical trials for SC451, an iPSC-derived pancreatic islet cell therapy for Type 1 diabetes, and SG293, an in vivo... -
Sana Biotechnology Announces Groundbreaking 14-Month Durability Data for Hypoimmune-Modified Islet Cell Transplantation (UP421) in Type 1 Diabetes Without Immunosuppression, Published in The New England Journal of Medicine
GlobeNewswire (Sana Biotechnology) USA Overview Sana Biotechnology announced groundbreaking long-term durability data for its hypoimmune-modified islet cell transplant UP421 in Type 1 Diabetes patients, demonstrating 14 months of sustain... -
Sana Biotechnology Advances Phase 1 Clinical Trial for Immunosuppression-Free iPSC-Derived Islet Cell Therapy UP421 for Type 1 Diabetes
AAII USA Overview Sana Biotechnology is actively progressing its Phase 1 clinical trial for UP421, an allogeneic islet cell product engineered with its Hypoimmune Platform (HIP) technology for type 1 diabetes, aiming to eliminate the nee... -
Sana Biotechnology to Announce Q1 Financial Results and Hypoimmune Cell Therapy Pipeline Progress at June Investor Conferences
Stock Titan USA Overview Sana Biotechnology is scheduled to present its Q1 2026 financial results and recent business updates on its hypoimmune cell therapy and in vivo gene editing platforms at multiple investor conferences in June 2026... -
Avaí Bio Achieves GMP Milestone for Anti-Aging Cell Therapy; Beam Therapeutics Targets Accelerated Approval for BEAM-302; Sana Partners with Mayo Clinic for Type 1 Diabetes
Newswire.ca Canada Overview Multiple biotech companies reported significant advancements: Avaí Bio completed its GMP-grade Master Cell Bank (MCB) for the α-Klotho anti-aging program, paving the way for preclinical and clinical trials. Be... -
Sana Biotechnology to Initiate Hypoimmune Cell Therapy and In Vivo CAR T Trials This Year, with Data Expected Within 12 Months
TradingView USA Overview Sana Biotechnology is set to commence clinical trials for two key platforms this year: a hypoimmune cell therapy targeting Type 1 diabetes and an in vivo CAR T platform for oncology and autoimmune diseases. Initi... -
Avaí Bio Establishes GMP-Grade Master Cell Bank for Alpha-Klotho Anti-Aging Program, Advancing Cell Therapy Toward Commercialization
PR Newswire (via USA News Group) USA Overview Avaí Bio has achieved a critical manufacturing milestone by completing its GMP-grade Master Cell Bank (MCB) for the alpha-Klotho anti-aging program. This MCB ensures a high-quality, standardi... -
Sana Biotechnology Reports 14-Month Positive Clinical Results for Immunosuppression-Free iPSC-Derived Islet Cell Transplant in Type 1 Diabetes
Simply Wall St (via Nasdaq:SANA) USA Overview Sana Biotechnology announced continued positive clinical results from its study of iPSC-derived islet cell transplantation (UP421) for Type 1 diabetes, spanning 14 months without immunosuppre...
1